Synergistic inhibitory effects of transplatin and beta-hydroxyisovalerylshikon on carcinoma A431 cells involve epidermal growth factor receptor.
Treatment of human epidermoid carcinoma A431 cells with transplatin (trans-DDP) and beta-hydroxyisovalerylshikon (beta-HIVS) together had a strong inhibitory effect on A431 cells. By contrast, trans-DDP and beta-HIVS by themselves, at the same respective concentrations, had practically no effect. The tyrosine kinase activities of v-Src and epidermal growth factor (EGFR) were inhibited by each of the two agents alone and strongly inhibited by combination. The observed synergistic inhibitory effect on the growth of A431 cells might have resulted from the inhibition of EGFR by trans-DDP, as well as by beta-HIVS.
Xu
Ying
Y
Laboratory of Biological Chemistry, School of Pharmaceutical Sciences, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, 142-8555, Tokyo, Japan.
Nakajo
Shigeo
S
Nakaya
Kazuyasu
K
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D002945:Cisplatin / Q000008:administration & dosage*; D004357:Drug Synergism; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000378:metabolism*; D006801:Humans; D009285:Naphthoquinones / Q000008:administration & dosage*; D015688:Oncogene Protein pp60(v-src) / Q000037:antagonists & inhibitors; D010766:Phosphorylation; D014407:Tumor Cells, Cultured / Q000187:drug effects* / Q000378:metabolism; D014443:Tyrosine / Q000378:metabolism
D009285:Naphthoquinones; C118460:beta-hydroxyisovalerylshikonin; C034697:transplatin; D014443:Tyrosine; D066246:ErbB Receptors; D015688:Oncogene Protein pp60(v-src); D002945:Cisplatin